v3.26.1
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
As previously reported
Cumulative Effect, Period of Adoption, Adjustment
Consideration paid for Arbuz
Purchase of ReKassa shares
Total equity attributable to the shareholders'
Total equity attributable to the shareholders'
As previously reported
Total equity attributable to the shareholders'
Cumulative Effect, Period of Adoption, Adjustment
Total equity attributable to the shareholders'
Consideration paid for Arbuz
Common Stock
Common Stock
As previously reported
Additional paid in capital
Additional paid in capital
As previously reported
Retained earnings
Retained earnings
As previously reported
Retained earnings
Cumulative Effect, Period of Adoption, Adjustment
Retained earnings
Consideration paid for Arbuz
Accumulated other comprehensive loss
Accumulated other comprehensive loss
As previously reported
Accumulated other comprehensive loss
Cumulative Effect, Period of Adoption, Adjustment
Non-controlling interest
Non-controlling interest
As previously reported
Non-controlling interest
Consideration paid for Arbuz
Non-controlling interest
Purchase of ReKassa shares
Shares issued, beginning of period (in shares) at Mar. 31, 2023                   59,659,191 59,659,191                          
Equity, beginning of period at Mar. 31, 2023 $ 783,742 $ 770,736       $ 790,291 $ 777,285     $ 59 $ 59 $ 164,162 $ 164,162 $ 644,467 $ 647,064     $ (18,397) $ (34,000)   $ (6,549) $ (6,549)    
Equity, beginning of period (Cumulative effect of adoption of ASU 2018-12) at Mar. 31, 2023     $ 13,006         $ 13,006               $ (2,597)       $ 15,603        
Equity, beginning of period (Cumulative adjustment from adoption of ASC 326) at Mar. 31, 2023     $ (22,772)         $ (22,772)               $ (22,772)                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                
Stock based compensation (in shares)                   662,622                            
Stock based compensation 19,627         19,627       $ 1   19,626                        
Disposal of FF Ukraine 0         (6,549)               (6,549)             6,549      
Purchase of subsidiary shares       $ 9,097 $ 256       $ 5,457               $ 5,457           $ 3,640 $ 256
Other comprehensive income (1,824)         (1,824)                       (1,824)            
Foreign currency translation adjustments, net of tax effect 12,075 12,075       12,075                       12,075            
Net income/(loss) 378,519 374,952       379,107               379,107             (588)      
Shares issued, end of period (in shares) at Mar. 31, 2024                   60,321,813                            
Equity, end of period at Mar. 31, 2024 1,178,720         1,175,412       $ 60   183,788   999,710       (8,146)     3,308      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                
Delivered stock awards from previous year (in shares)                   215,878                            
Delivered stock awards from previous year 3,092         3,092           3,092                        
Forfeited stock based compensation (in shares)                   (310,700)                            
Forfeited stock based compensation 0                                              
Stock based compensation (in shares)                   765,958                            
Stock based compensation 59,593         59,593       $ 1   59,592                        
Other compensation (in shares)                   1,000                            
Other compensation 138         138           138                        
Purchase of subsidiary shares       $ (887)         $ 2,175               $ 2,175           $ (3,062)  
Other comprehensive income 11,852         11,852                       11,852            
Foreign currency translation adjustments, net of tax effect (104,102) (104,102)       (104,102)                       (104,102)            
Net income/(loss) $ 76,158 84,521       76,287               76,287             (129)      
Shares issued, end of period (in shares) at Mar. 31, 2025 60,993,949                 60,993,949                            
Equity, end of period at Mar. 31, 2025 $ 1,224,564 $ 1,214,358       1,224,447       $ 61   246,610   1,078,172       (100,396)     117      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                
Forfeited stock based compensation (in shares)                   (82,906)                            
Forfeited stock based compensation 0                                              
Stock based compensation (in shares)                   381,538                            
Stock based compensation 68,047         68,047           68,047                        
Sale of Comrun LLP (117)                                       (117)      
Other comprehensive income (10,589)         (10,589)                       (10,589)            
Foreign currency translation adjustments, net of tax effect 54,046         54,046                       54,046            
Net income/(loss) $ 153,328         153,328               153,328                    
Shares issued, end of period (in shares) at Mar. 31, 2026 61,292,581                 61,292,581                            
Equity, end of period at Mar. 31, 2026 $ 1,489,279         $ 1,489,279       $ 61   $ 314,657   $ 1,231,500       $ (56,939)     $ 0